

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: SpeedX Pty Ltd

主要联系人姓名: Jennifer Maher

主要联系人职务: 首席财务官

公司网址: www.speedx.com.au

公司地址: Suite G16, National Innovation Centre, Australian Technology Park, 4 Cornwallis Street, Eveleigh NSW 2015

公司未上市

公司简介

SpeedX 致力于开发具有高经济效益的医用基因快速诊断技术。SpeedX 拥有一系列广泛、受良好保护的专利组合, 这包括用于实时 PCR 的 MNAzyme qPCR、用于基因分型的 PASS 技术, 以及等温信号扩增技术。SpeedX 的技术在用于点突变检测、单核苷酸多态性分析、复合扩增上, 已证实比目前市场上领先的 TaqMan 技术更佳灵敏、精确。SpeedX 的技术已被用于设计开发精密的诊断分析中。

SpeedX 正在寻求合作伙伴共同开拓不断增长的体外诊断(IVD)以及遗传性疾病检测市场。

SpeedX 同时寻求拓展其卓越技术到非体外诊断领域的机会, 包括(但不局限于)食品检测、农业、兽医、环境测试等。

关键技术或领先技术

SpeedX 的专利技术具有独到特点, 有助于推动测试普及度至现有的诊断市场, 并创造新的市场需求。这些技术包括:

- 多组分核酸(MNAzymes): 是一组包含 DNA 的酶。通过简单、低价的改良, 可对多种不同目标分析物进行灵敏、特定的多重检测。
- 脱氧核酶(DNAzymes): 是一组包含 DNA 的酶 (SpeedX 自 The Scripps Research Institute 获得该技术在人体和动物健康领域的独家授权)

- **PASS:** 对引物和 / 或多组分核酸的成分进行创新性的设计，从而使其能对基因突变、等位基因变异、病毒、细菌菌株等进行高度灵敏的测试。
- **EzyAmp:** 一种利用限制性酶的等温信号扩增级联反应。
- **DNA-only-cascade (DOC):** 一种利用核酸催化酶的等温信号放大级联反应。

类别

诊断类:肿瘤诊断

备注: **SpeedX** 的技术也可用在分子诊断领域内以开发精准、快速、具有高经济效益的试剂盒。

病毒诊断

备注: **SpeedX** 正顺应不同领域学科权威期许，研发一系列的化验。这些大多是还未被满足的市场需求或是需要多重或抗药性检测的精密化验。首批新型化验进展顺利，目前正接受第三方评估。

关键技术或领先技术的发展阶段

产品已经上市

备注: **SpeedX** 拥有多个在不同研发阶段的项目，这些项目各自适合不同的合作伙伴。某些项目需要当地的合作伙伴来进行临床测试，而其他更先进的技术已被 **SpeedX** 的合作伙伴整合成为体外检测用产品。

合作机会

SpeedX 寻求针对中国市场的合作伙伴，共同开发并销售 qPCR 体外诊断或化验，和对传染病、遗传类疾病、其他领域（比如：食品检验、农业）等的检测。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: SpeedX Pty Ltd

Key contact name: Jennifer Maher

Job title of key contact: Chief Financial Officer

Company website address: www.SpeedX.com.au

Company address: Suite G16, National Innovation Centre, Australian Technology Park, 4 Cornwallis Street, Eveleigh NSW 2015

The company is Unlisted.

ABOUT THE COMPANY

SpeedX has been focused on the development of cost effective and rapid detection technologies for genetic-based medical diagnostics. The company owns an extensive, well protected patent portfolio which includes solutions for real time PCR (MNAzyme qPCR), for genotyping (PASS technology) and isothermal signal amplification. SpeedX technologies have proven advantages over the current market leader TaqMan for the sensitive and specific detection of point mutations and SNPs, as well as for multiplexing. The company's technologies have been applied in the design and development of sophisticated diagnostic assays.

SpeedX is seeking partners in the growing IVD market and the detection of genetic diseases field. The company is also looking to expand its superior technologies in other non IVD fields including but not limited to food testing, agriculture, veterinary and environmental testing.

KEY OR LEAD TECHNOLOGY

SpeedX's proprietary technologies have differentiating features that drive penetration of tests into existing diagnostic markets and create new markets. These technologies include:

- Multi-component nucleic acids (MNAzymes): enzymes composed of DNA that can be easily and cheaply adapted for sensitive, specific multiplexed detection of many different target analytes;
- DNAzymes: enzymes composed of DNA (through an exclusive license from The Scripps Research Institute – exclusive rights for human and animal health);
- PASS: novel design feature for primers and/or MNAzyme components for highly sensitive multiplexed detection of gene mutations, allelic variations, and viral and bacterial strains;
- EzyAmp: an isothermal signal amplification cascade utilising restriction enzymes; and
- DNA-only-cascade (DOC): an isothermal signal amplification cascade utilising catalytic nucleic acid enzymes.

Category

Diagnostics: Diagnostics oncology

Note: SpeedX technologies also enable the development of accurate, speedy and cost competitive test kits in the molecular diagnostic field.

Diagnostics virology

SpeedX is currently developing a number of assays desired by KOLs (Key Opinion Leaders) of their respective field. These are mostly unmet needs or sophisticated assays which require multiplexing and/or drug resistance detection. First group of assays have progressed well and are currently under 3rd party evaluation.

Point of development of key or lead technology

Product on the market

Note: Speedx has multiple projects at different stages which are suitable for different partners, some require a local partner to conduct local clinical trials and others are more advanced and these technologies have been incorporated into IVD products by our partners.

OPPORTUNITIES SOUGHT

Seeking partners who can co-develop and commercialise tests/assays for qPCR in IVD, detection of infectious diseases, genetic diseases and other fields (ie. food testing, agriculture.) for the Chinese market.